Shukra Pharmaceuticals Intrinsic Value
Shukra Pharmaceuticals (SHUKRAPHAR) median intrinsic value is ₹12.98 from 9 valuation models (range ₹10–₹29), vs current price ₹32.44 — -60.0% downside (Trading Above Calculated Value), margin of safety -100.0%. For current market price and key ratios, visit SHUKRAPHAR stock price BSE.
SHUKRAPHAR Valuation Methods Summary — DCF, Graham Number & P/E
Shukra Pharmaceuticals intrinsic value across 9 models vs current price ₹32.44 — upside/downside and value range per method. Browse SHUKRAPHAR financial statements for revenue, profit, balance sheet and cash flow data.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹9.73 | ₹7.78 - ₹11.68 | -70.0% | EPS: ₹0.20, Sector P/E: 22x |
| Book Value Method | asset | ₹28.64 | ₹25.78 - ₹31.50 | -11.7% | Book Value/Share: ₹14.32, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹14.55 | ₹13.10 - ₹16.01 | -55.1% | Revenue/Share: ₹7.27, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹12.98 | ₹11.68 - ₹14.28 | -60.0% | EBITDA: ₹4.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹24.70 | ₹19.76 - ₹29.64 | -23.9% | CF Growth: 15.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹9.73 | ₹8.76 - ₹10.70 | -70.0% | EPS Growth: 8.0%, Fair P/E: 6.4x |
| Growth Adjusted P/E | growth | ₹9.73 | ₹8.76 - ₹10.70 | -70.0% | Revenue Growth: 6.0%, Adj P/E: 15.5x |
| ROE Based Valuation | profitability | ₹21.82 | ₹19.64 - ₹24.00 | -32.7% | ROE: 12.7%, P/E Multiple: 12x |
| Graham Defensive Method | conservative | ₹9.73 | ₹8.76 - ₹10.70 | -70.0% | EPS: ₹0.20, BVPS: ₹14.32 |
SHUKRAPHAR Intrinsic Value vs Market Price — All Valuation Models
Shukra Pharmaceuticals fair value range ₹10–₹29 vs current market price ₹32.44 across 9 valuation models. Compare with SHUKRAPHAR fair value to assess whether the stock is under or overvalued.
SHUKRAPHAR Intrinsic Value Analysis — Undervalued or Overvalued?
Shukra Pharmaceuticals median intrinsic value ₹12.98, current price ₹32.44 — Trading Above Calculated Value by 60.0%, margin of safety -100.0%.
What is the intrinsic value of SHUKRAPHAR?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Shukra Pharmaceuticals (SHUKRAPHAR) is ₹12.98 (median value). With the current market price of ₹32.44, this represents a -60.0% variance from our estimated fair value.
The valuation range spans from ₹9.73 to ₹28.64, indicating ₹9.73 - ₹28.64.
Is SHUKRAPHAR undervalued or overvalued?
Based on our multi-method analysis, Shukra Pharmaceuticals (SHUKRAPHAR) appears to be trading above calculated value by approximately 60.0%.
SHUKRAPHAR Financial Health — Key Ratios vs Industry Benchmarks
Shukra Pharmaceuticals financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 9.29 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 12.7% | Industry Standard: 15%+ | Above 10% | Measures shareholder return efficiency |
| Operating Margin | -7.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 0.37x | Industry Standard: 1.0x+ | Below 0.5x | Measures asset utilization efficiency |
SHUKRAPHAR Cash Flow Quality — Operating & Free Cash Flow
Shukra Pharmaceuticals operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹8 Cr | ₹8 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹-5 Cr | ₹-6 Cr | Negative Cash Flow | 3/10 |
| March 2023 | ₹3 Cr | ₹1 Cr | Positive Free Cash Flow | 7/10 |
| March 2022 | ₹8 Cr | ₹7 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹1 Cr | ₹0 Cr | Positive Operating Cash Flow | 6/10 |